Immunologic agents (e.g., mercaptopurines, methotrexate, etc.) and biologic agents (e.g., infliximab) are often used to treat Crohn’s disease, but the carcinogenic risk of these drugs has been a point of contention among experts. Recently, experts from Dartmouth University School of Medicine discussed this issue in the journal “inflammatory bowel disease,” and the results of their discussion are transcribed below Younger men with Crohn’s disease are at highest risk), with a correspondingly higher risk of non-melanotic skin cancer and melanoma, and women with Crohn’s disease may be at increased risk of cervical cancer with the corresponding drugs. Summary: Although the use of immunologic and anti-TNF agents may increase the risk of lymphoma and skin cancer, it is worth noting that the baseline risk is still very low. For some patients, the benefits of these agents far outweigh the disadvantages of their potential carcinogenic risks. Therefore, patients and clinicians should weigh the balance of pros and cons of the relevant drug therapy according to the patient’s own situation.